Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07654842 · ClinicalTrials.gov registry record · Phase 4
Fasenra: An Asthma Study
A Phase 4 study, sponsored by Endeavor Health.
- Not yet
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT07654842 is a Phase 4 study that has not yet begun recruiting, run by Endeavor Health. The registered enrollment target is 40 participants.
The verdict
NCT07654842, a Phase 4 study, has not yet begun recruiting, sponsored by Endeavor Health.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.
Interventions
- DRUG Benralizumab
- DRUG Budesonide-albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2028-01-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07654842
The ClinicalTrials.gov registry entry for NCT07654842 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benralizumab is the first listed.
NCT07654842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07654842 about?
NCT07654842 is a clinical study titled "Fasenra: An Asthma Study". The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as w...
What is the current status of trial NCT07654842?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2026-07-01. Estimated completion is 2028-01-01.
What interventions are being tested in trial NCT07654842?
The interventions under investigation include: Benralizumab (DRUG), Budesonide-albuterol (DRUG).
Who is sponsoring clinical trial NCT07654842?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.